Abstract
Background Perioperative ischemic stroke is a rare but devastating complication. Mechanical thrombectomy is a promising therapeutic method, but very little data is available on its efficacy and safety. This study aims to answer this question by comparing the clinical outcomes of perioperative and community-onset stroke patients after endovascular therapy.
Methods A retrospective cohort study was conducted on a total of 35 perioperative and 584 community-onset acute ischemic stroke patients who underwent endovascular thrombectomy at our hospital over the past 3.5 years. The recanalization rate, clinical recovery and cerebral hemorrhage within 90 days after therapy were compared between these two patient groups.
Results Endovascular thrombectomy provided perioperative and community-onset ischemic stroke patients with comparable rates of successful reperfusion (mTICI ≥ 2b grade) (97.1% vs. 97.3%; P = 0. 967) and favorable functional recovery (mRS ≤ 2) (51.4% vs. 43.3%, P = 0.348), with no increase in severe intracranial hemorrhage (0% vs. 2.6% and 1.0%, for hematoma ≥ 30% of infarcted tissue and intraventricular hemorrhage, respectively) within 90 days. In addition, perioperative stroke patients had higher prevalence of atrial fibrillation (42.9 % vs. 26.7 %; P = 0.038) and intracranial cerebral artery stenosis without clear embolism (17.1 % vs. 3.8 %; P < 0.001) than community-onset stroke patients.
Conclusions Endovascular thrombectomy is an effective and safe therapeutic approach for patients with perioperative ischemic stroke, although the results need to be validated by further studies with larger populations. Atrial fibrillation and large artery stenosis may contribute to the pathogenesis of perioperative ischemic stroke.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from Zhejiang Provincial Basic and Public Welfare Research Program (No. GF21H020023); Zhejiang Provincial Medicine and Health Research Foundation (grant number: 2021RC141).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The studies involving human participants were reviewed and approved by the Ethics Committee of Taizhou Hospital, Zhejiang Province, China (K20181204).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the corresponding author, Y.L. and S.K. The data are not publicly available because it contains information that could compromise the privacy of the research participants.
